Imedos Health

What Imedos Health does

Imedos Health GmbH is a Jena, Germany-based privately held medical device company (founded 1996) that develops, manufactures, and distributes hardware and software systems for non-invasive, contactless imaging of the human retina to assess microvascular and cardiovascular health. Its product portfolio centers on two proprietary imaging modalities - Static Vessel Analysis (morphological assessment of retinal vessels, e.g., arteriole-to-venule ratio for cardiovascular risk) and Dynamic Vessel Analysis or DVA 3.0 (worldwide unique flicker-light stimulation method for measuring real-time vessel function and autoregulation) - supplemented by the RCrodent small-eye preclinical system, the IOPstim ophthalmodynamometry research tool, and the VesselMap analysis software. The company monetizes primarily through one-time hardware sales with installed-based service, maintenance, and remote-support contracts; first-generation systems were priced in the six-figure range, while the third-generation DVA 3.0 has been reset to "market-rate" pricing to broaden clinical adoption.

Imedos holds 32 patents across Germany, Europe, USA, Japan, China, and worldwide, and its technology is cited in more than 1,000 international peer-reviewed publications (including journals such as Hypertension, American Heart Association). The commercial scale today is anchored by 340+ deployed systems in 22 countries, generated through a hybrid go-to-market combining direct enterprise sales to research institutions and academic medical centers with an international distributor network (formalized by ALF Distribution GmbH for Germany, the EU, and Switzerland). Customer evidence spans university hospitals (Jena, Basel, Zurich, Düsseldorf, Huddersfield, Oklahoma HSC), federal research bodies (DLR, NASA), practicing ophthalmologists, cardiologists, and optometrists, with named clinical use cases in cardiovascular risk stratification, hypertension, neurology (stroke and Alzheimer's risk), nephrology, and ophthalmology.

The company's stated strategic posture is a deliberate expansion from a research-institution core into the broader clinical-practice market (practicing ophthalmologists and cardiologists), supported by DVA 3.0 pricing reset, new clinical-vertical partnerships (notably COVID-19 endothelial-dysfunction research in 2020 and ongoing DLR/NASA microgravity programs from 2020), and explicit interest in securing an external investor to scale worldwide market access. With 15 employees, founder/management ownership, and no disclosed external funding or revenue figures, Imedos operates as a niche specialist positioned between research instrumentation and emerging clinical microvascular diagnostics.

Name

Imedos Health

Legal name

Imedos Health GmbH

Website

https://imedos.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

Imedos Health GmbH, founded 1996 in Jena, Germany, develops and distributes patented medical-device systems for non-invasive retinal vascular analysis. It serves research institutions, academic medical centers, and clinical practices across 22 countries with 340+ installed Static and Dynamic Vessel Analysis systems.

Ownership category

akta.pro rank

Product category

Ophthalmic Diagnostic Equipment

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

akta.pro secondary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• Retinal vessel analysis
• Medical imaging devices
• Cardiovascular diagnostics
• Microcirculation assessment
• Ophthalmic diagnostic equipment

Headquarters

HQ city

Jena

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Systems - Hardware: Sale of retinal vessel analysis medical devices including Static Vessel Analysis systems, Dynamic Vessel Analysis (DVA 3.0) systems, RCrodent animal model systems, and IOPstim systems. Hardware systems are the primary revenue driver. Devices have been reduced to market-appropriate pricing in third generation.
2. Customer Service and Support: Installation, maintenance, technical support, remote support (via Splashtop), and training services for Imedos systems. Training can be conducted on-site or online via remote maintenance.
3. Software Analysis Systems: VesselMap software offering rapid, repeatable semi-automated analyses of retinal vessel parameters for research and clinical purposes.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Imedos Health develops and sells medical device systems for non-invasive retinal vascular analysis based on Static and Dynamic Vessel Analysis methods. The product portfolio includes the Dynamic Vessel Analyzer 3.0 (DVA 3.0) hardware for dynamic analysis using flicker light stimulation, the VesselMap software for static vessel parameter analysis, RCrodent Systems for animal model research, and the IOPstim system for ophthalmodynamic measurement of retinal venous pressure.

Product overview

Imedos Health develops and distributes advanced medical device systems for retinal vascular analysis based on Static and Dynamic Vessel Analysis methods. The product portfolio includes the Dynamic Vessel Analyzer 3.0 (DVA 3.0) hardware for dynamic analysis using flicker light, the VesselMap software for static vessel parameter analysis, the RCrodent Systems for animal model research, and the IOPstim system for ophthalmodynamic measurement. These products offer non-invasive access to patient microcirculation through retinal vessel examination, enabling visualization and analysis of vascular changes, function, and regulation for cardiovascular diagnostics, research, and clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Static Vessel Analysis (Statische Gefäßanalyse) Non-invasive, contact-free examination system for the morphology of retinal blood vessels, associated with general vascular health and global microcirculation status. Serves as an integral component of modern cardiovascular diagnostics for research institutions, hospitals, and clinical practices.
• Dynamic Vessel Analysis / Dynamic Vessel Analyzer 3.0 (DVA / DVA 3.0) Worldwide unique method for non-invasive investigation of retinal vessel function and autoregulation using flicker light-modulated video sequences that capture diameter changes along vessels time-variantly. Targets research institutions and clinical practices in cardiology, neurology, ophthalmology, and cardiometabolic prevention.
• RCrodent Systems The only commercially available solution for contactless imaging and fluorescence angiography for smallest eyes, enabling static and dynamic microcirculation investigation in animal models. For preclinical and animal research users.
• IOPstim System (Ophthalmodynamometrie) Research system that enables simple and pain-free increase of intraocular pressure for gentle measurement of retinal venous pressure, supporting research of eye diseases such as glaucoma. Imedos is the only provider of this technology.
• VesselMap Software Software offering rapid, repeatable semi-automated analyses of retinal vessel parameters for research and clinical purposes, including AV-ratio and vessel diameter assessment.

Quantifiable outcome

• More than 80% of cardiovascular diseases can be prevented if risk factors are recognized and eliminated early — Imedos technology enables such early detection.
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• University of DüsseldorfcoreStrategic or Co-development Partner · 1 January 2021Scientists from the University of Düsseldorf collaborate with Imedos in parabolic flight campaigns to study the behavior of eye microvessels in weightlessness. The first successful parabolic flight campaign was conducted in Paderborn in 2021. Follow-up campaigns have been conducted from Bordeaux using Novespace's A310 Zero G aircraft.
• German Aerospace Center (DLR)coreStrategic or Co-development Partner · 1 January 2020DLR funds a series of studies starting in 2020 investigating how weightlessness affects the central microcirculation. Imedos participates as one of six project partners, using its DVA system for high-precision retinal imaging during parabolic flights. Project led by Prof. Dr. Dr. med. Christian Jung at University Hospital Düsseldorf. The studies aim to improve safety of future space missions.
• University Hospital Jena (UKJ)coreStrategic or Co-development Partner · 1 January 2020University Hospital Jena and Imedos Systems jointly conduct studies on whether functional analysis of retinal vessels can predict COVID-19 disease progression. Dr. Daniel Vilser leads a clinical trial analyzing retinal vessels of COVID-19 patients. The study found endothelial function disorders in the majority of patients studied, demonstrating the technology's clinical utility.
• University Hospital ZurichcoreStrategic or Co-development Partner · 1 January 2020Researchers at University Hospital Zurich conducted studies showing SARS-CoV-2 triggers severe vascular inflammation throughout the body. The findings support using Imedos dynamic vessel analysis to identify patients with endothelial dysfunction who are at high risk for severe COVID-19 progression. Prof. Dr. med. Frank Ruschitzka reported that further investigations with retinal vessel analysis are planned.
• ALF Distribution GmbHcoreChannel Partner/ Reseller/ DistributorImedos appointed ALF Distribution GmbH (Aachen, Germany) as its official distributor for retinal vessel analysis systems covering Germany, the European Union, and Switzerland. The partnership focuses on cardiovascular research markets. ALF Distribution has extensive experience in identifying high-quality non-invasive vascular diagnostic technologies and direct device distribution.
• NASAcoreStrategic or Co-development PartnerNASA collaborates with DLR on bed rest studies investigating the impact of weightlessness on the human body. Imedos DVA technology is included in these studies to analyze changes in the eye and microcirculation. Part of efforts to prepare for long-duration missions such as sending humans to Mars.
• Novespace (A310 Zero G)minorStrategic or Co-development PartnerNovespace operates the A310 Zero G aircraft used for parabolic flight campaigns in Bordeaux. Imedos collaborates with Novespace to conduct microgravity research, adapting devices to withstand g-forces of levels 9-10.9 during weightlessness experiments.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• Itamar Medical (ZOLL Itamar): Itamar Medical's EndoPAT measures endothelial function non-invasively for cardiovascular risk assessment, addressing a closely related clinical question to Imedos's dynamic retinal vessel analysis and competing for the same cardiology and screening research budgets.
• Optovue (Visionix): Optovue pioneered OCT angiography (OCTA), a non-invasive modality that visualizes retinal vasculature without contrast agents, offering a competing approach to Imedos's DVA for assessing retinal microcirculation.
• AtCor Medical (SunTech Medical): AtCor (now part of SunTech) commercializes the SphygmoCor system for non-invasive central blood pressure and arterial stiffness measurement, used in cardiovascular research alongside retinal vascular analysis tools like Imedos's DVA.
• Phelcom Technologies: Phelcom builds portable, AI-enabled retinal imaging cameras (Eyer) for screening and tele-ophthalmology, an emerging approach that overlaps with Imedos's vision of using retinal imaging for systemic disease risk assessment, especially in resource-limited settings.

Broad incumbents

• Carl Zeiss Meditec: Zeiss Meditec is a global leader in ophthalmic diagnostic devices (OCT, fundus imaging, perimetry) and surgical microscopy. As a broad incumbent it offers overlapping retinal imaging capabilities used by the same ophthalmology research and clinical customers that Imedos serves, though as part of a much larger portfolio.
• Nidek: Nidek manufactures a wide range of ophthalmic diagnostic devices including fundus cameras and OCT systems that overlap with Imedos's retinal imaging use cases in ophthalmology clinics and research institutions globally.
• Topcon Healthcare: Topcon is a major Japanese ophthalmic imaging company whose fundus cameras, OCT systems, and AI-driven screening platforms compete broadly with Imedos in retinal imaging for cardiovascular and ophthalmic research and clinical screening applications.
• Canon Medical Systems (Ophthalmic): Canon's ophthalmic division produces retinal cameras (CR-2, CX-1) used in screening and research, competing with Imedos for ophthalmology and cardiovascular-risk-screening customers, particularly in primary-care and optometry settings.

Direct peers

• Heidelberg Engineering: Heidelberg Engineering (also German, Heidelberg-based) is the most direct peer: it makes the Spectralis platform combining OCT and confocal fundus imaging for retinal diagnostics, and is widely used in ophthalmology research and clinical practice, overlapping with Imedos's retinal imaging and vascular analysis use cases.
• iCare (Revenio Group): iCare (part of Revenio) provides ophthalmic diagnostic devices including fundus imaging, perimetry, and tonometers used by the same clinical and research ophthalmology customers that adopt Imedos, with overlapping distribution channels in Europe.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/imedos
• LinkedInlinkedin.com/company/imedos-health
• Facebookfacebook.com/imedoshealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imedos Health